These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 9919742)

  • 1. [Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus].
    Fábryová L; Cagán S
    Bratisl Lek Listy; 1998; 99(3-4):138-45. PubMed ID: 9919742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Fabroya L; Cagan S
    Bratisl Lek Listy; 1998 Mar; 99(3-4):138-45. PubMed ID: 9664734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects.
    Griffin BA; Minihane AM; Furlonger N; Chapman C; Murphy M; Williams D; Wright JJ; Williams CM
    Clin Sci (Lond); 1999 Sep; 97(3):269-76. PubMed ID: 10464051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
    Krentz AJ
    Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities in lipoprotein metabolism in hemodialysis patients.
    Königer M; Quaschning T; Wanner C; Schollmeyer P; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S248-50. PubMed ID: 10412790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dyslipoproteinemias of diabetes.
    Steiner G
    Atherosclerosis; 1994 Oct; 110 Suppl():S27-33. PubMed ID: 7857380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein atherogenicity: an overview of current mechanisms.
    Griffin BA
    Proc Nutr Soc; 1999 Feb; 58(1):163-9. PubMed ID: 10343354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of anomalies of low density lipoproteins (LDL) in atherogenicity].
    Chapman JM; Guérin M; Bruckert E
    Bull Acad Natl Med; 2001; 185(1):35-7; discussion 38-9. PubMed ID: 11474567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.
    Lamarche B; Lemieux I; Després JP
    Diabetes Metab; 1999 Sep; 25(3):199-211. PubMed ID: 10499189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus.
    Niemeijer-Kanters SD; Dallinga-Thie GM; de Ruijter-Heijstek FC; Algra A; Erkelens DW; Banga JD; Jansen H
    Atherosclerosis; 2001 May; 156(1):209-16. PubMed ID: 11369016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are plasma lipoproteins responsible for the excess atherosclerosis in diabetes?
    Nikkilä EA
    Acta Endocrinol Suppl (Copenh); 1985; 272():27-30. PubMed ID: 3869424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
    Temelkova-Kurktschiev T; Hanefeld M
    Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):75-9. PubMed ID: 15031770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes.
    Esteghamati A; Asnafi S; Eslamian M; Noshad S; Nakhjavani M
    Endocr Res; 2015; 40(1):14-9. PubMed ID: 24832870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of small dense low-density lipoproteins as coronary risk factor in diabetic and non-diabetic Korean populations.
    Yoon Y; Song J; Park HD; Park KU; Kim JQ
    Clin Chem Lab Med; 2005; 43(4):431-7. PubMed ID: 15899660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
    Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low density lipoprotein subclass distribution in children with diabetes mellitus.
    Alabakovska SB; Labudovic DD; Tosheska KN; Spiroski MZ; Todorova BB
    Bratisl Lek Listy; 2008; 109(4):155-9. PubMed ID: 18814430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.